// App-Quantinova.ai

: Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Researchers

Presenter

  • Michael Byrne

Principal Investigators

  • Mark G. Frattini

  • Oliver G. Ottmann

  • Ioannis Mantzaris

  • Martin Wermke

  • Daniel J. Lee

  • Daniel Morillo

  • Arne Scholz

  • Stuart Ince

  • Ray Valencia

  • Fabricio Souza

  • Raul Cordoba

Medical Centers

  • Vanderbilt University Medical Center, Department of Medicine, Hematology and Stem Cell Transplant Section, Nashville, TN

  • Columbia University Medical Center, New York, NY

  • Cardiff University, Department of Hematology Division of Cancer and Genetics, Cardiff, United Kingdom

  • Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

  • University Heart Center Dresden, Dresden, Germany

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • Bayer, Berlin, Germany

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

Locations

  • United States

  • United Kingdom

  • Germany

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute myelocytic leukemia

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved